Insmed Incorporated (NASDAQ:INSM) Receives $35.50 Consensus Price Target from Analysts

Share on StockTwits

Insmed Incorporated (NASDAQ:INSM) has earned an average recommendation of “Buy” from the ten research firms that are currently covering the company, Marketbeat.com reports. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $35.50.

A number of analysts recently issued reports on INSM shares. Morgan Stanley set a $37.00 price target on shares of Insmed and gave the stock a “buy” rating in a report on Friday, November 1st. BidaskClub upgraded shares of Insmed from a “sell” rating to a “hold” rating in a research report on Monday, November 25th. HC Wainwright restated a “buy” rating on shares of Insmed in a research report on Thursday, October 31st. ValuEngine raised shares of Insmed from a “hold” rating to a “buy” rating in a research note on Monday, November 25th. Finally, Zacks Investment Research cut Insmed from a “buy” rating to a “hold” rating in a report on Friday, September 27th.

NASDAQ:INSM traded up $0.39 during trading hours on Friday, reaching $23.36. The company had a trading volume of 667,031 shares, compared to its average volume of 1,059,539. Insmed has a 1-year low of $11.31 and a 1-year high of $33.13. The firm has a market cap of $2.06 billion, a PE ratio of -5.60 and a beta of 3.04. The business’s 50 day moving average price is $19.66 and its 200-day moving average price is $20.69. The company has a debt-to-equity ratio of 1.19, a current ratio of 6.97 and a quick ratio of 6.70.

Insmed (NASDAQ:INSM) last issued its quarterly earnings data on Wednesday, October 30th. The biopharmaceutical company reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.01). The firm had revenue of $38.89 million for the quarter, compared to analyst estimates of $35.89 million. Insmed had a negative return on equity of 114.68% and a negative net margin of 291.19%. During the same period in the previous year, the business earned ($1.14) EPS. On average, analysts expect that Insmed will post -2.91 earnings per share for the current fiscal year.

In other news, CAO John Goll sold 25,000 shares of the company’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $20.80, for a total transaction of $520,000.00. Insiders own 4.95% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in INSM. Point72 Hong Kong Ltd acquired a new position in shares of Insmed during the 2nd quarter worth approximately $34,000. Riverhead Capital Management LLC purchased a new position in Insmed during the second quarter worth approximately $73,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Insmed by 17.2% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,818 shares of the biopharmaceutical company’s stock worth $103,000 after buying an additional 854 shares during the last quarter. NumerixS Investment Technologies Inc boosted its stake in Insmed by 26.5% during the second quarter. NumerixS Investment Technologies Inc now owns 4,807 shares of the biopharmaceutical company’s stock worth $123,000 after buying an additional 1,007 shares during the last quarter. Finally, Tyers Asset Management LLC boosted its stake in Insmed by 1,002.5% during the second quarter. Tyers Asset Management LLC now owns 7,056 shares of the biopharmaceutical company’s stock worth $181,000 after buying an additional 6,416 shares during the last quarter.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE┬« (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

Read More: What Factors Can Affect Return on Equity?

Analyst Recommendations for Insmed (NASDAQ:INSM)

Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.